Cure of Helicobacter pylori infection in the elderly: Effects of eradication on gastritis and serological markers

Alimentary Pharmacology and Therapeutics

Volumn 10, Issue 6, 1996, Pages 1021-1027

  Pilotto, A ^a,g   Di Mario, F ^b   Franceschi, M ^a   Leandro, G ^c   Soffiati, G ^d   Scagnelli, M ^e   Bozzola, L ^f   Valerio, G ^a  

^a SAN BORTOLO HOSPITAL   (Italy)

^b UNIVERSITY OF PADOVA   (Italy)

^c Department of Gastroenterology ^*  (Italy)

^d Clinical Biochemistry Laboratories   (Italy)

^e Microbiology Unit   (Italy)

^f Clinical Pathology Unit   (Italy)

^g Ospedale Regionale 'S Bortolo   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN; CLARITHROMYCIN; METRONIDAZOLE; OMEPRAZOLE;

ADULT; AGED; ARTICLE; BACTERIAL INFECTION; CONTROLLED STUDY; DRUG EFFICACY; DRUG TOLERANCE; DYSPEPSIA; ENDOSCOPY; FEMALE; GASTRITIS; HELICOBACTER PYLORI; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

EID: 0029830883     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.1996.88260000.x     Document Type: Article

References (32)

1. Graham DY, Malaty HM, Evans DG, et al. Epidemiology of Helicobacter pylori in an asymptomatic population in the United States. Effect of age, race and socioeconomic status. Gastroenterology 1991; 100: 1495-501.
2. Veldhuyzen Van Zanten SJ, Pollak PT, Best LM, Bezanson GS, Marrie T. Increasing prevalence of Helicobacter pylori infection with age: continuous risk of infection in adults rather than cohort effect. J Infect Dis 1994; 169: 434-7.
3. Pilotto A, Fabrello R, Franceschi M, et al. Helicobacter pylori infection in asymptomatic elderly subjects living at home or in a nursing-home: effects on gastric function and nutritional status. Age Ageing 1996; 25: 245-9.
4. Green LK, Graham DY. Gastritis in the elderly. Gastroenterol Clin North Am 1990; 19: 273-92.
5. Meyer BR, Reidenberg MM. Clinical pharmacology and ageing. In: Evans JG, Williams TF, eds. Oxford Textbook of Geriatric Medicine. Oxford University Press: Oxford, 1992: 105-16.
6. Kang JY, Tay HH, Wee A, et al. Effect of colloidal bismuth subcitrate on symptoms and gastric histology in non-ulcer dyspepsia. A double blind placebo controlled study. Gut 1990; 31: 476-80.
7. Kosunen TU, Seppala K, Sarna S, Sipponen P. Diagnostic value of decreasing IgG, IgA, and IgM antibody titres after eradication of Helicobacter pylori. Lancet 1992; 339: 893-5.
8. Plebani M, Di Mario F, Stanghellini V, Delle Fave G. Serological tests to monitor treatment of Helicobacter pylori. Lancet 1992; 340: 51-2.
9. Hunter FM, Correa P, Fontham E, et al. Serum pepsinogens as markers of response to therapy for Helicobacter pylori gastritis. Dig Dis Sci 1993; 38: 2081-6.
10. Wagner S, Haruma K, Gladziwa U, et al. Helicobacter pylori infection and serum pepsinogen A, pepsinogen C, and gastrin in gastritis and peptic ulcer: significance of inflammation and effect of bacterial eradication. Am J Gastroenterol 1994; 89: 1211-8.
11. Pilotto A, Franceschi M, Leandro G, et al. The clinical usefulness of serum pepsinogens, specific IgG anti-HP antibodies and gastrin for monitoring Helicobacter pylori treatment in older people. J Am Geriatr Soc 1996; 44: 665-70.
12. Misiewicz JJ, Tytgat GNJ, Goodwin CS, et al. The Sydney System: a new classification of gastritis. In; Working Party Reports of the 9th World Congress of Gastroenterology. Melbourne: Blackwell Scientific Publications, 1990: 1-10.
13. Talley NJ, Newell DG, Ormand JE, et al. Serodiagnosis of Helicobacter pylori: comparison of enzyme-linked immunosorbent assays. J Clin Microbiol 1991; 29: 1635-9.
14. Chiba N, Rao BV, Rademaker JW, Hunt RW. Meta-analysis of the efficacy of antibiotic therapy in eradicating H. pylori. Am J Gastroenterol 1992; 87; 1716-27.
15. Marshall BJ. Helicobacter pylori. Am J Gastroenterol 1994; 89: S116-28.
16. Noach LA, Bertola MA, Schwartz MP, Rauws EAJ, Tytgat G. Treatment of H. pylori infection: an evaluation of various therapeutic trials. Eur J Gastroenterol Hepatol 1994; 6: 585-92.
17. Walsh JH, Peterson WL. The treatment of Helicobacter pylori infection in the management of peptic ulcer disease. N Engl J Med 1995; 333: 984-91.
18. De Boer W, Driessen W, Jansz A, Tytgat G. Effect of acid suppression on efficacy of treatment for Helicobacter pylori infection. Lancet 1995; 345: 817-20.
19. Bell GD. Conference report: duodenal ulcer trials reported at the European Helicobacter pylori Study Group. Edinburgh 1995. Aliment Pharmacol Ther 1996; 10: 49-54.
20. Czinn S, Carr H, Aronoff S. Susceptibility of Campylobacter pyloridis to three macrolide antibiotics (Erythromycin, Roxythromycin and CP 62.993) and Rifampin. Antimicrob Agents Chemother 1986; 30: 328-9.
21. Retsema J, Girard A, Schelkly W, et al. Spectrum and mode of action of Azithromycin (CP-62.993), a new 15-membered-ring macrolide with improved potency against Gram-negative organisms. Antimicrob Agents Chemother 1987; 31: 1939-47.
22. Marchi M, Vacondio R, Bagnulo A, Mengoli M. Azithromycinomeprazole. Treatment for eradication of Helicobacter pylori. Minerva Gastroenterol Dietol 1994; 40: 47-9.
23. Al-Assi MT, Genta RM, Karttunen TJ, Cole RA, Graham DY. Azithromycin triple therapy for Helicobacter pylori infection: azithromycin, tetracycline and bismuth. Am J Gastroenterol 1995; 90: 403-5.
24. Dal Bò N, Ferrana M, Salandin S. et al. Azithromycin: a new useful therapeutic strategy for the eradication of Helicobacter pylori infection. Am J Gastroenterol 1994; 89: 1368 (A332).
25. Darmaillac V, Bouchard S, Lamouliatte H, Megraud F. Macrolides and Helicobacter pylori. Determination of MICs and effect of pH. Gut 1995; 37 (Suppl. 1): A91(Abstract).
26. Bazzoli F, Zagari RM, Fossi S, et al. Short-term low-dose triple therapy for the eradication of Helicobacter pylori. Eur J Gastroenterol Hepatol 1994; 6: 773-7.
27. Dalla Libera M, Pazzi P, Carli G, et al. High effectiveness and safety of one-week antibiotic regimen in Helicobacter pylori eradication. Aliment Pharmacol Ther 1996; 10: 203-6.
28. Pilotto A, Vianello F, Di Mario F, et al. Effect of age on gastric acid, pepsin, pepsinogen group A and gastrin secretion in peptic ulcer patients. Gerontology 1994; 40: 253-9.
29. Lind T, Cederberg C, Olansson M, Olbe L. Omeprazole in elderly duodenal ulcer patients: relationship between reduction in gastric acid secretion and fasting plasma gastrin. Eur J Clin Pharmacol 1991; 40: 557-60.
30. Pilotto A, Di Mario F, Battaglia G, et al. The efficacy of two doses of omeprazole for short- and long-term peptic ulcer treatment in the elderly. Clin Ther 1994; 16: 935-41.
31. Valle J, Seppala K, Sipponen P, Kosunen T. Disappearance of gastritis after eradication of Helicobacter pylori. Scand J Gastroenterol 1991; 26: 1057-65.
32. Rugge M, Di Mario F, Cassaro M, et al. Pathology of the gastric antrum and body associated with Helicobocter pylori infection in non-ulcerous patients : is the bacterium a promoter of intestinal metaplasia? Histopathology 1993; 22: 9-15.